{"name":"CVRx","slug":"cvrx","ticker":"CVRX","exchange":"NASDAQ","domain":"cvrx.com","description":"CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.","hq":"Minneapolis, MN","founded":0,"employees":"223","ceo":"Nadim Yared","sector":"Neuromodulation / Medical Devices","stockPrice":5.76,"stockChange":0.54,"stockChangePercent":10.34,"marketCap":"$152M","metrics":{"revenue":59072000,"revenueGrowth":19.6,"grossMargin":86.2,"rdSpend":11132000,"netIncome":-53306000,"cash":72303000,"dividendYield":0,"peRatio":-3.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Barostim patent cliff ($0.0B at risk)","drug":"Barostim","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-02-24","type":"regulatory","headline":"CVRx Announces FDA Approval of Barostim Neo","summary":"CVRx announced that the FDA has approved the Barostim Neo system for the treatment of resistant hypertension.","drugName":"Barostim Neo","sentiment":"positive"},{"date":"2021-11-10","type":"earnings","headline":"CVRx Reports Third Quarter 2021 Financial Results","summary":"CVRx reported revenue of $13.4 million for the third quarter of 2021, a 25% increase from the same period in 2020.","drugName":"","sentiment":"neutral"},{"date":"2020-06-01","type":"deal","headline":"CVRx Announces Collaboration with Medtronic","summary":"CVRx announced a collaboration with Medtronic to develop a new neuromodulation therapy for the treatment of chronic pain.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9EN1lmTXktX0V2RnJvV2dacHM1emttaW4zSkxXNEE5QmhIcVp5YkxlUmJ6LTFWOGpvc3VkNy1IeVdlal9GVWt4MmMyS01fWEtjSklIWnBTV0x4dEppcUJVUEVPUkJLUFF5QmxjWG5iTm93MkRIdHcycHh0dFR5QQ?oc=5","date":"2026-04-08","type":"pipeline","source":"baoquankhu1.vn","summary":"Pharma News: Will CVRX benefit from government policy - Day Trade & Reliable Price Breakout Alerts - baoquankhu1.vn","headline":"Pharma News: Will CVRX benefit from government policy - Day Trade & Reliable Price Breakout Alerts - baoquankhu1.vn","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQemNHRGxkZU5URDBuNEFwVlBvLWR2bk1jQjFDRE9nMTRteEktRWlKeFlpYTY5OW83eTFwbGJKSm41SFBMV09UOVhMcE5VME5adk52UVRoVFluQ0xPV3pSYWhkVVlFLWZhTEVWR0tPXzFjYUI3Q2NLVHJLNUp6TGpJd1JPX3FtZWJPUUltV1c2aVlhTktGbW5RUjZ6VEoyNjZiTzVXUGs2TW9Bd1FRcTRCYm1SZGxCc3Fqa0hQZ2pvTzhLNnNfYU40NENFc1R0aWRxcnFyZnlOblFRM0s5eVVCTnVsajdIRVE?oc=5","date":"2026-02-19","type":"pipeline","source":"PR Newswire","summary":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX - PR Newswire","headline":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX","sentiment":"neutral"},{"date":"2026-02-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQMTFpb3RocVptdlVEc1Q3bkdHUGpxblNIRmNqSVppRGZxbkZWMG5IczQ2MmhfUWJXZ0VZTUxXdlJhUmFsQldmU0hRN2xtX2JCcjRNWUk1SjVpTEQyTWFfeWktbzczcE5KM19yQTRFSXhhUlkzV21sZ0Y0ZG5aWFdsQ1A1T2k2a1dXdjB3eUY2MU9hbC01WkFZMG0tbXBLRk1kemFxYWgtUUM0SVBORFRmczlZeHBqT0hRbkRpa0FLRlVKRHNJSERELVFDNmNGVTdrb21vZ2FyZmxJNWFpVjVTNzVXT0hIOFJna0pkYXhHd1Njak83c0FMUW9MalF0N2hkVkNFRS1tTFhfVElPd2ZLeTNEck5sVFpTY2xuWkpkcGkzUkhScTFHRXVpN21xOENEaGc?oc=5","date":"2026-01-30","type":"pipeline","source":"globenewswire.com","summary":"CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating - globenewswire.com","headline":"CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQeHhnbmhnT3E1TnBpcDBEQ2RwZWxMUDk1STE3RGlYLUhVR0x5SElPYmU0SFBpbXl5UUNRSk9yRHQzQWY1SWk0ZW9NUDdSaVBxT0JXUXRPN0FHWDRlS0tZRmpwRl9ZTE11XzFOMWtrc1lLSUM5NVhvaUFYcGZ5Y0t0MG9NbkFPQVRpMnd4SFpsZ2lvTFBVLXBLUHppSzAyMmxMbmpzV2l1c1ZVeDMyX0x3c3NSXzdsTXVWR2R2eFVLa3JncXdUb3QxRXhjbHlBRGh0R0cwMDdjTUdMYTQ1eFFmZ1NwWHExN0t2c1ZVOG1JUzZZM0YwaWs5UEJteGg?oc=5","date":"2026-01-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Aligos Therapeutics (ALGS) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Aligos Therapeutics (ALGS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQWjVJbmZGcGhJcEJWeGVhZG1VZ1FBNm5NcHdITFpMS1VPZDFITnloc3A4RUUtM0xGWThyRkh1VDVmWWtiUVctLTU3RGxfSDVUWHBZdGF0OG9pQmU0LUdoNWdPcmNYV0x1bkJfQ0ZtZXB6Tk5naXJJeDVySmZrX29EMnBLNFE1THBwTExUc0lR?oc=5","date":"2026-01-12","type":"earnings","source":"Yahoo Finance","summary":"CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance - Yahoo Finance","headline":"CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNWFNhZ21kMHQ4NE1DdWFJT0pjX25YRTlyU3FPamtYSVpRckZjT0VHR2ZoeEw4UEdxaUtIY2JBajdVMWw4WHVEWVFDaktRWF93VzRDM28tQ3VLcG1hdktJSDVtZkQ4Nm9MbWFwcm9SVFVSVVl3U3NCVzFYSkZfZS1ibHM5ME9UOGFXNmZRcE1EUHhkRmdkOWd4aDRnZk43d2kyYkxqUDh0VE5mVk85aFEyWEN6N25HSFZEVGFhdERseThkWDM2Vk9HNlUyeWFxTUJBMnBEZ1Z3?oc=5","date":"2025-12-22","type":"pipeline","source":"globenewswire.com","summary":"CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference - globenewswire.com","headline":"CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxOVGFVb2FxcmVEeE1hZG50UkxVM3htV29UOTMtdUtsSWp4ZGlvUGlXVUlneFdTVnRFVXduSlZHNmNGTXVXclpiT1Y5a1VYbk94MExpMDYwUVdPU0FIWXVvVHQ2eW1BZ3FueXNZQ21Ram9Ccm9BaS1NdkpRMjhneERCVkpCNDc5MjdpcTNPaWx3V09RVlNZbEZtUHNBWFg1YTJjcWxSQzBjYTQyU0xrdk1BVk1yWEY0aEVZcE14UjlRbEIwTnBORlFuQVVmeFgyMXlpMTRSTXNESVVYbzZMXzM3YTFrM3NCQWotcHZSakJyRi1JdllrcC1iNC1oUTlIaHNEZmVKX0J5RQ?oc=5","date":"2025-10-22","type":"earnings","source":"globenewswire.com","summary":"CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 - globenewswire.com","headline":"CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPS3UtcENGckF3emk2NUx1cHVBZS1icVBpakx6VUxCcHh5dEVlUGNKdUlTMDhlN2lkR1o1LTdNMUhGeDNuUTlUR2RJLXlfb3BHMUU1cno0T3VqTlp3bmV3X01aYkRrZjhpMWdlUVN3VWIwcE1kM3p1WjNHT1VXQU50NGo0a0l4bzRzZENZbGxOX2wxZW00aVFUSDRn?oc=5","date":"2024-05-15","type":"pipeline","source":"MassDevice","summary":"CVRx bolsters its executive ranks with hires from Abbott, Medtronic - MassDevice","headline":"CVRx bolsters its executive ranks with hires from Abbott, Medtronic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTnlHU2FkSnIybTRTN0FWLXJ3a3plOF94SDZhLUQxTmoxZ0F0OUlYZ2R5eU5Zb0hHOVhPYU0tRHBCc2V1VkhfbmFONUw0VDhtN0ZlUW1PTk9fY0FtTTRuVzFQT21rTERYMm11dGdqU245SVJ4bmtmY3Z1cjZrSnQwbXFJRHBlUV96Sk9vQ1p3ZncxWVFXRWVKamVoWTY2ZkpScXFkdnJWNUI5cjhMNVJCT0wxbzROWkI4aUkw?oc=5","date":"2024-04-16","type":"trial","source":"dicardiology.com","summary":"CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim - dicardiology.com","headline":"CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1pVHJyR1dPOGx3SnRNNXJRQllZdjdhSUxGZWVhX3N0X3Viajk5WjhZUUkxb1JtQW5MVngtWVJwN2tsS1hDVkQzS2EwYlNuX2h5YnZLbjFFZVVKN3hXYmc4cDUzb0lrdVZoLXV1ZjliUzNaNHI3US1ENm1DOA?oc=5","date":"2024-04-16","type":"trial","source":"MassDevice","summary":"CVRx has more data supporting long-term benefits of Barostim - MassDevice","headline":"CVRx has more data supporting long-term benefits of Barostim","sentiment":"neutral"}],"patents":[{"drugName":"Barostim","drugSlug":"barostim","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Boston Scientific","Medtronic","St. Jude Medical"],"therapeuticFocus":["Neuromodulation","Resistant Hypertension"],"financials":{"source":"sec_edgar+yahoo","revenue":56651000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":56651000,"period":"2025-12-31"},{"value":51292000,"period":"2024-12-31"},{"value":51292000,"period":"2024-12-31"},{"value":39295000,"period":"2023-12-31"},{"value":39295000,"period":"2023-12-31"}],"grossProfit":48340000,"grossProfitHistory":[{"period":"2025-12-31","value":48340000},{"period":"2024-12-31","value":42958000},{"period":"2023-12-31","value":33039000},{"period":"2022-12-31","value":17470000}],"rdSpend":11132000,"rdSpendHistory":[{"period":"2025-12-31","value":11132000},{"period":"2024-12-31","value":11131000},{"period":"2023-12-31","value":11633000},{"period":"2022-12-31","value":9952000}],"sgaSpend":88473000,"operatingIncome":-51265000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-51265000},{"period":"2024-12-31","value":-59490000},{"period":"2023-12-31","value":-43103000},{"period":"2022-12-31","value":-42527000}],"netIncome":-53306000,"netIncomeHistory":[{"period":"2025-12-31","value":-53306000},{"period":"2024-12-31","value":-59965000},{"period":"2023-12-31","value":-41199000},{"period":"2022-12-31","value":-41428000}],"eps":-2.04,"epsHistory":[{"period":"2025-12-31","value":-2.04},{"period":"2024-12-31","value":-2.65},{"period":"2023-12-31","value":-1.99},{"period":"2022-12-31","value":-2.02}],"cash":75708000,"cashHistory":[{"period":"2025-12-31","value":75708000},{"period":"2024-12-31","value":105933000},{"period":"2023-12-31","value":90569000},{"period":"2022-12-31","value":106194000}],"totalAssets":104794000,"totalLiabilities":65470000,"totalDebt":50504000,"equity":39324000,"operatingCashflow":-40170000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-40170000},{"period":"2024-12-31","value":-39144000},{"period":"2023-12-31","value":-39021000},{"period":"2022-12-31","value":-42677000}],"capex":-580000,"capexHistory":[{"period":"2025-12-31","value":-580000},{"period":"2024-12-31","value":-1361000},{"period":"2023-12-31","value":-591000},{"period":"2022-12-31","value":-685000}],"freeCashflow":-40750000,"dividendsPaid":null,"buybacks":0,"employees":223,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":22009000,"ebit":-10524000,"ebitda":-10339000,"period":"2025-12-31","revenue":16024000,"epsBasic":-0.46,"netIncome":-11934000,"rdExpense":3000000,"epsDiluted":-0.46,"grossProfit":13825000,"operatingIncome":-11184000},{"sga":21875000,"ebit":-11393000,"ebitda":-11199000,"period":"2025-09-30","revenue":14690000,"epsBasic":-0.49,"netIncome":-12870000,"rdExpense":3146000,"epsDiluted":-0.49,"grossProfit":12753000,"operatingIncome":-12268000},{"sga":23357000,"ebit":-13266000,"ebitda":-13073000,"period":"2025-06-30","revenue":13589000,"epsBasic":-0.57,"netIncome":-14736000,"rdExpense":2469000,"epsDiluted":-0.57,"grossProfit":11450000,"operatingIncome":-14376000},{"sga":21232000,"ebit":-12314000,"ebitda":-12130000,"period":"2025-03-31","revenue":12348000,"epsBasic":-0.53,"netIncome":-13766000,"rdExpense":2517000,"epsDiluted":-0.53,"grossProfit":10312000,"operatingIncome":-13437000},{"sga":20240000,"ebit":-9202000,"ebitda":-9024000,"period":"2024-12-31","revenue":15342000,"epsBasic":-0.43,"netIncome":-10651000,"rdExpense":2805000,"epsDiluted":-0.43,"grossProfit":12771000,"operatingIncome":-10274000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.76,"previousClose":5.22,"fiftyTwoWeekHigh":11.3,"fiftyTwoWeekLow":4.37,"fiftyTwoWeekRange":"4.37 - 11.3","fiftyDayAverage":7.87,"twoHundredDayAverage":7.97,"beta":0.87,"enterpriseValue":125609624,"forwardPE":-3.1,"priceToBook":5.23,"priceToSales":2.58,"enterpriseToRevenue":2.13,"enterpriseToEbitda":-2.55,"pegRatio":0,"ebitda":-49212000,"ebitdaMargin":-83.3,"freeCashflow":-23050750,"operatingCashflow":-39567000,"totalDebt":59395000,"debtToEquity":204,"currentRatio":10.2,"returnOnAssets":-27.2,"returnOnEquity":-107,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":11.17,"targetHighPrice":14,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":9.3,"institutionHeldPercent":64.1,"sharesOutstanding":26430915,"floatShares":18356770,"sharesShort":1746275,"shortRatio":6.47,"shortPercentOfFloat":6.6,"epsTrailing":-2.01,"epsForward":-1.87,"revenuePerShare":2.25,"bookValue":1.1,"officers":[{"age":59,"name":"Mr. Kevin  Hykes","title":"President, CEO & Director"},{"age":64,"name":"Dr. Philip B. Adamson M.D., M.Sc.","title":"Chief Medical Officer"},{"age":51,"name":"Mr. Robert Allen John","title":"Chief Revenue Officer"},{"age":42,"name":"Mr. Jared  Oasheim","title":"Chief Financial Officer"},{"age":56,"name":"Mr. Brent  Binkowski","title":"Chief Operating Officer"},{"age":62,"name":"Mr. Paul  Verrastro","title":"Chief Marketing & Strategy Officer"},{"age":61,"name":"Mr. Gregory  Morrison","title":"Chief Human Resources Officer"},{"age":null,"name":"Ms. Bonnie  Handke M.B.A., R.N.","title":"Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.cvrx.com","phone":"763 416 2840"}}